63 results
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
reimbursement and pricing for our medicines from government and third-party payors and risks relating to the success of our patient assistance programs … under the Genentech collaboration.
Collaboration revenue consisted of non-refundable upfront payments, development milestones as well as reimbursement
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
officers is entitled to receive amounts earned during his or her term of service, including unpaid salary, reimbursement of unreimbursed business … or reimbursement of reasonable legal and professional fees, untaken holiday and any payment for the settlement of potential claims against the Group
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government and third-party payors … and our distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government and third
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
officers is entitled to receive amounts earned during his or her term of service, including unpaid salary, reimbursement of unreimbursed business …
The Committee reserves the right to make payments it considers reasonable under a settlement agreement, including payment or reimbursement of reasonable legal
S-3ASR
IMCR
Immunocore Holdings plc
20 Mar 24
Automatic shelf registration
8:51pm
and our distribution and marketing partners’ ability to obtain coverage and adequate reimbursement and pricing for our medicines from government … and charges of, and reimbursement of the applicable expenses incurred by, the depositary.
Books of Depositary
The depositary maintains ADS holder records
10-K
EX-97.1
iefq8dqs
28 Feb 24
Annual report
7:33am
10-K
EX-10.14
x2r1 fqlt6
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
2o73kq1vxabxs ec
28 Feb 24
Annual report
7:33am
10-K
EX-10.12
kkil1isr0tk
28 Feb 24
Annual report
7:33am
10-K
x8db2fyszhmx
28 Feb 24
Annual report
7:33am
6-K
EX-99.2
58sng1
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
ryvlmnw 3mrk
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.2
jam9oqe5ivrdskm
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.3
5esvrqy2fsm srmcfah
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
jadp02k 8f
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
gairf5cklg ctagh
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.4
dp3v0s wlhxx0uwu
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.3
dllo20wpepanj5
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
6-K
EX-99.2
ax0nf
9 Nov 22
Index to Unaudited Condensed Consolidated Interim Financial Statements
7:15am
424B7
ueoldf1
30 Sep 22
Prospectus with selling stockholder info
4:15pm